Cefpodoxime: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
Line 8: Line 8:
==Category==
==Category==


[[Cephalosporins]], third generation.
[[Cephalosporins]], Third-Generation.


==US Brand Names==
==US Brand Names==

Revision as of 13:41, 15 January 2014

Cefpodoxime Proxetil
VANTIN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings
Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Overview

Cefpodoxime (marketed as the prodrug cefpodoxime proxetil by Pharmacia & Upjohn under the trade name Vantin®) is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment. Pfizer, the parent company of Pharmacia & Upjohn, markets Cefpodoxime proxetil under the trade name Simplicef® for veterinary use. The dose range in dogs is 5-10 mg/kg body weight, administered orally, once a day. Outside the US, Cefpodoxime proxetil is marketed as Banan®.

Category

Cephalosporins, Third-Generation.

US Brand Names

VANTIN®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages

References

http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050674s015,050675s018lbl.pdf